FUSD:F:F-Fidelity UCITS SICAV - Fidelity US Quality Income UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.584

Change

+0.02 (+0.19)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-20 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.06 (-0.01%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.04 (+0.06%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.03 (+0.20%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.45 (+0.19%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

+0.07 (+0.89%)

USD 41.48B
0ZC:F Zscaler Inc

-0.30 (-0.16%)

USD 37.92B
BSND:F Danone SA

-0.10 (-0.71%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.76 (-0.60%)

USD 24.77B

ETFs Containing FUSD:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.20% 17% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.20% 16% F 33% F
Trailing 12 Months  
Capital Gain 3.85% 47% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.85% 45% F 47% F
Trailing 5 Years  
Capital Gain 116.29% 72% C 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.29% 72% C 52% F
Average Annual (5 Year Horizon)  
Capital Gain 14.59% 82% B 73% C
Dividend Return 14.59% 80% B- 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.80% 59% D- 87% B+
Risk Adjusted Return 123.62% 98% N/A 98% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike